Loading clinical trials...
Loading clinical trials...
A Phase-3, Randomized, Parallel Group, Open-label, Multicenter, Two-Arm Treatment Study to Evaluate the Efficacy and Safety of Weekly Paclitaxel Lipid Suspension Compared with Weekly Conventional Paclitaxel in the Patients with Platinum-Resistant/Refractory Recurrent High-grade Serous Epithelial Ovarian Cancer Including Fallopian Tube And/or Primary Peritoneal Cancer
Conditions
Interventions
Paclitaxel Lipid Suspension
Conventional paclitaxel or Taxol
Start Date
April 1, 2025
Primary Completion Date
December 1, 2025
Completion Date
March 1, 2026
Last Updated
March 10, 2025
NCT05271318
NCT04739800
NCT03113487
NCT04616534
NCT04718675
NCT04244552
Lead Sponsor
Jina Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions